Work

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-127390

Authors: William Pearse, Barbara Pro, Leo I. Gordon, Reem Karmali, Jane N. Winter, Shuo Ma, Amir Behdad, Andreas Klein, Adam M. Petrich, Borko Jovanovic, Sonali M. Smith, Andrew G Evans

Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Tufts Medical Center, University of Chicago, University of Rochester Medicine

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4253991105

Cites:

Cited by: 6

Related to: 10